Biography
Dr Nicolas Sprynski has over 10 years’ experience in academia, pharmaceutical R&D and biotechnology (ANTABIO). In academia, Dr Sprynski studied extensively virulence mechanism of highly pathogenic bacteria like Brucella spp. and developed alternative in vivo models of infection. As a drug discovery scientist he has a particular interest in antibiotic resistance/persistence mechanisms. At ANTABIO, Nicolas leads the internal biology discovery group and has responsibility for external research collaborations. Antabio have just been awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in cystic fibrosis patients.